EU REGISTERED MEDICAL DEVICE (CE MARKED) | CERTIFICATE OF FREE SALE (CFS) AVAILABLE

Luminossa TCA

Line: Pilingi | Presentation: Professional clinical TCA solution | EU Medical Device (CE)

Rapid action, Painless, No frost effect, No post-treatment sign, an instant result that improves over time, Suitable for all ages, not photosensitizer



KEY ACTIVES / AKTIVNYE KOMPONENTY

- The LUMINOSSA TCA Peeling- Medium to deep is a medical CLASS I product based on TRICHLOROACETIC ACID (TCA) stabilized with alpha-hydroxy acids. Also contains Mandelic Acid and KOJIC ACID .
- TCA: trichloroacetic acid (up to 12%) :
- KOJIC ACID (up to 6 %):
- It has high whitening properties. It works as an inhibitor of melanogenesis (Meta convenient process that regulates the production of melanin), the KOJIC ACID is specifically indicated in the treatment of melasma or chloasma, the photo-ageing and dark circles.

INDICATIONS / POKAZANIYA

- Rapid action, Painless, No frost effect, No post-treatment sign, an instant result that improves over time, Suitable for all ages, not photosensitizer
- Its unique formula in gel form allows the stabilization of TCA thanks to strong cocktails and weak acids present in the formulation and mixed with a stoichiometric manner to make the treatment stable, safe and effective.
- Components:
- Indicated in peeling to reduce signs of ageing (wrinkles relaxation, dull skin), acne, keratosis and superficial to deep cleanse the skin and resources. Strong action against the D-pigmentation (Both dermis hyperpigmentation and post-inflammatory origin), wrinkles, photoaging, in acne scars. It is giving brightness and smoothness of the skin.

REGULATORY & QUALITY GOVERNANCE

Status: APPROVED (2026-11-26) | Reviewer: Etternity Dermal, S.L. · Technical Direction
Regulatory Classification: EU Registered Medical Device (CE) - Certificate of Free Sale (CFS) | Audience: Professional Clinic & Cabin
Claims / Regulatory Standard: EU Registered Medical Device (CE / MDR) · Certificate of Free Sale (CFS) | Markets: EU, MENA, LATAM, CIS
RESTRICTED DOCUMENTATION NOTICE: Full clinical injection/needling protocols, SDS and regulatory dossiers are excluded from public builds and provided strictly via controlled access.